Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» multiple sclerosis
multiple sclerosis
After a long, painful revamp, Merck KGaA scores key OK for once-defunct MS drug cladribine
Endpoints
Fri, 08/25/17 - 09:57 am
Merck KGaA
MS
multiple sclerosis
cladribine
Drug blocked by European regulators improves quality of life for MS patients
Drug Delivery Business News
Fri, 08/18/17 - 12:09 pm
Europe
MS
multiple sclerosis
cladribine
Lawmakers dig into 'skyrocketing' MS costs with probe into 7 drugmakers
Fierce Pharma
Thu, 08/17/17 - 11:48 pm
multiple sclerosis
MS
drug pricing
Bayer
Biogen
Merck KGaA
Novartis
Sanofi
Teva Pharmaceutical
Roche
Biotechs Find Strength In Numbers In Treating Multiple Sclerosis
Investors Business Daily
Fri, 07/21/17 - 10:25 am
MS
multiple sclerosis
Roche
Celgene
Novartis
Biogen
ozanimod
Gilenya
Ocrevus
Extavia
How Biogen Inc. Makes Most of Its Money
Motley Fool
Thu, 07/13/17 - 05:43 pm
Biogen
Tecfidera
Tysabri
MS
multiple sclerosis
EMA Restricts Use of Biogen MS Drug
RAPS.org
Sun, 07/9/17 - 11:39 am
Europe
EMA
Biogen
MS
multiple sclerosis
Zinbryta
Biogen aims to block Tecfidera generics with flurry of lawsuits
Bizjournals.com
Tue, 07/4/17 - 11:22 pm
Biogen
Tecfidera
generics
MS
multiple sclerosis
Novartis
Sandoz
Mylan Labs
2 Pharma Buyout Targets That May Surprise You
Motley Fool
Tue, 06/27/17 - 09:46 am
Biogen
Bristol-Myers Squibb
M&A
MS
multiple sclerosis
immuno-oncology
Roche's Ocrevus racks up more positive MS data in relapsing and primary progressive forms
Fierce Pharma
Sat, 06/24/17 - 09:14 am
Roche
Ocrevus
MS
multiple sclerosis
EMA Recommends New HCV, Cancer and MS Drugs for Approval
RAPS.org
Sat, 06/24/17 - 09:11 am
Europe
EMA
hepatitis C
multiple sclerosis
breast cancer
renal cell carcinoma
AbbVie
Maviret
Gilead Sciences
Vosevi
Biogen
Amgen
Samsung Bioepis
biosimilars
Humira
Novartis
Kisqali
EUSA
Fotivda
Mylan's Copaxone copy could face another hold-up with FDA info request
Fierce Pharma
Fri, 06/16/17 - 09:56 pm
Mylan
Copaxone
FDA
generics
Teva Pharmaceutical
MS
multiple sclerosis
Roche looks into PML report for Ocrevus patient
BioPharma Dive
Thu, 05/25/17 - 11:25 am
Roche
PML
Ocrevus
Genentech
MS
multiple sclerosis
Celgene touts ozanimod MS data, but disability benefit weak over rival med
Fierce Biotech
Mon, 05/22/17 - 09:41 am
Celgene
ozanimod
MS
multiple sclerosis
Biogen
Avonex
Teva crashes out of laquinimod MS program
BioPharma Dive
Tue, 05/9/17 - 10:17 am
Teva Pharmaceutial
MS
multiple sclerosis
laquinimod
Troubled Teva’s successor to Copaxone just failed a big PhIII test for multiple sclerosis
Endpoints
Sun, 05/7/17 - 11:11 am
Teva Pharmaceutical
Copaxone
MS
multiple sclerosis
laquinimod
Active Biotech
Celgene highlights MS drug in diversification push
BioPharma Dive
Thu, 04/27/17 - 05:47 pm
Celgene
MS
multiple sclerosis
ozanimod
Novartis' Gilenya patent loss sets MS market up for battle with early generics
Fierce Pharma
Thu, 04/13/17 - 06:49 pm
Novartis
Gilenya
MS
multiple sclerosis
generics
4 Reasons Why Roche Will Have the Best Growth in Big Pharma... and 1 Reason Why It Won't
Motley Fool
Wed, 04/12/17 - 10:33 am
Roche
Tecentriq
Perjeta
HER-2 postive breast cancer
Ocrevus
MS
multiple sclerosis
diagnostics
generics
biosimilars
Bass Battled U.S. Drug Patents and Prices But Lost to ‘Cabal’
Bloomberg
Mon, 04/10/17 - 10:06 am
Kyle Bass
patents
drug pricing
AMPYRA
Acorda Therapeutics
multiple sclerosis
Why Roche's New Drug Is Bad News For Biogen
Barron's
Sun, 04/9/17 - 12:20 pm
Roche
Biogen
Ocrevus
multiple sclerosis
MS
Tysabri
Tecfidera
Pages
« first
‹ previous
…
6
7
8
9
10
11
12
13
14
…
next ›
last »